专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013034506A1 PDE10 MODULATORS 审中-公开
标题翻译： PDE10调制器
公开(公告)号：WO2013034506A1
公开(公告)日：2013-03-14
申请号：PCT/EP2012/067047
申请日：2012-09-03
申请人： F. HOFFMANN-LA ROCHE AG , BACHMANN, Stephan , FLOHR, Alexander , GROEBKE ZBINDEN, Katrin , KOERNER, Matthias , KUHN, Bernd , PETERS, Jens-Uwe , RUDOLPH, Markus
发明人： BACHMANN, Stephan , FLOHR, Alexander , GROEBKE ZBINDEN, Katrin , KOERNER, Matthias , KUHN, Bernd , PETERS, Jens-Uwe , RUDOLPH, Markus
IPC分类号： C07D231/14 , C07D233/90 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , A61P25/00 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/4196 , A61K31/422
CPC分类号： C07D471/04 , C07D231/14 , C07D233/90 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
摘要： The present invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 5 , W, X, X 1 , Y, Y 1 , Z and Z 1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.
摘要翻译：本发明涉及式（I）化合物，其中R 1，R 2，R 3，R 5，W，X，X 1，Y，Y 1，Z和Z 1如说明书和权利要求书中所定义，以及生理上可接受的盐它们。这些化合物抑制PDE10A，可用作药物。

2. 发明申请

WO2011154327A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS 审中-公开
标题翻译：含氮异氰酸酯化合物
公开(公告)号：WO2011154327A1
公开(公告)日：2011-12-15
申请号：PCT/EP2011/059234
申请日：2011-06-06
申请人： F. HOFFMANN-LA ROCHE AG , BLEICHER, Konrad , FLOHR, Alexander , GROEBKE ZBINDEN, Katrin , GRUBER, Felix , KOERNER, Matthias , KUHN, Bernd , PETERS, Jens-Uwe , RODRIGUEZ SARMIENTO, Rosa Maria
发明人： BLEICHER, Konrad , FLOHR, Alexander , GROEBKE ZBINDEN, Katrin , GRUBER, Felix , KOERNER, Matthias , KUHN, Bernd , PETERS, Jens-Uwe , RODRIGUEZ SARMIENTO, Rosa Maria
IPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/506 , A61P25/00 , A61P35/00
CPC分类号： C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A 1 , A 2 , (a), R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.
摘要翻译：本发明涉及式（I）的新型含氮杂芳基化合物，其中A1，A2，（a），R1，R2，R3，R4，R5和R6如说明书和权利要求书中所定义，以及其生理上可接受的盐和酯。这些化合物抑制PDE10A，可用作药物。

3. 发明申请

WO2010139707A1 2-AMINOOXAZOLINES AS TAAR1 LIGANDS 审中-公开
标题翻译： 2-AMINOOXAZOLINES as TAAR1 LIGANDS
公开(公告)号：WO2010139707A1
公开(公告)日：2010-12-09
申请号：PCT/EP2010/057669
申请日：2010-06-02
申请人： F. HOFFMANN-LA ROCHE AG , DECORET, Guillaume , GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger
发明人： DECORET, Guillaume , GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger
IPC分类号： C07D263/28 , A61K31/421 , A61P25/00
CPC分类号： C07D263/28
摘要： The invention relates to compounds of formula (I) wherein R 1 is halogen; R 2 is lower alkyl or lower alkyl substituted by halogen; R 2' is hydrogen, lower alkyl or lower alkyl substituted by halogen; X is a bond, -CH 2 -, -CH 2 CH 2 - or -CH 2 CH 2 CH 2 -; Y is phenyl or cyclohexyl; and n is 0, 1 or 2; or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及其中R 1为卤素的式（I）化合物; R2是被卤素取代的低级烷基或低级烷基; R2'是氢，被卤素取代的低级烷基或低级烷基; X是键，-CH 2 - ， - CH 2 CH 2 - 或-CH 2 CH 2 CH 2 - ; Y是苯基或环己基; 且n为0,1或2; 或其药学上合适的酸加成盐。式I化合物对TAAR1受体具有活性，因此适用于治疗抑郁症，焦虑障碍，双相情感障碍，注意缺陷多动障碍，应激相关疾病，精神病性精神病，精神分裂症，神经系统疾病，帕金森病，神经变性疾病，阿尔茨海默病，癫痫，偏头痛，药物滥用和代谢紊乱，饮食失调，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律障碍以及心血管障碍。

4. 发明申请

WO2009019149A1 PYRIDINECARBOXAMIDE AND BENZAMIDE DERIVATIVES AS TAAR1 LIGANDS 审中-公开
标题翻译：吡啶甲酰胺和苯甲酰胺衍生物作为TAAR1配体
公开(公告)号：WO2009019149A1
公开(公告)日：2009-02-12
申请号：PCT/EP2008/059790
申请日：2008-07-25
申请人： F. HOFFMANN-LA ROCHE AG , GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , STALDER, Henri
发明人： GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , STALDER, Henri
IPC分类号： C07C233/66 , C07D213/82 , C07D235/06 , C07D401/12 , C07D407/12 , A61K31/497 , A61K31/4439 , A61K31/444 , A61K31/44 , A61K31/404 , A61P3/00
CPC分类号： C07D213/80 , C07C233/66 , C07D213/82 , C07D235/08 , C07D401/12 , C07D405/12
摘要： The invention relates to a compound of formula (I) wherein R 1 , R 2 , W, L, X, n and o are defined herein. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及其中R1，R2，W，L，X，n和o如本文所定义的式（I）化合物。已经发现，式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意力缺陷多动障碍（ADHD），应激相关疾病，精神病性精神障碍如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病。

5. 发明申请

WO2009016088A1 THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS 审中-公开
标题翻译：使用苯甲酸衍生物治疗中枢神经系统疾病
公开(公告)号：WO2009016088A1
公开(公告)日：2009-02-05
申请号：PCT/EP2008/059698
申请日：2008-07-24
申请人： F. HOFFMANN-LA ROCHE AG , GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , STALDER, Henri
发明人： GALLEY, Guido , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , STALDER, Henri
IPC分类号： A61K31/166 , A61K31/167 , C07D213/00 , A61P9/12 , A61P9/00 , A61P25/00 , A61P3/00
CPC分类号： A61K31/166 , A61K31/167 , C07C233/65 , C07C233/75 , C07C235/56 , C07C237/40 , C07C255/57 , C07C311/16 , C07C311/21 , C07C317/44 , C07D205/06 , C07D211/14 , C07D213/82 , C07D231/12 , C07D263/32 , C07D275/06 , C07D295/155 , C07D295/26 , C07D401/04
摘要： The present invention relates to the use of a compound of formula (I), wherein R or a pharmaceutically acceptable acid addition salt thereof, for the manufacture of a medicament for the treatment of CNS disorders selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress- related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及式（I）化合物或其药学上可接受的酸加成盐在制备用于治疗选自抑郁症，焦虑障碍，双相性精神障碍，注意力的中枢神经系统疾病的药物中的用途缺血性多动障碍（ADHD），压力相关障碍，精神病性精神障碍如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢性疾病如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病。

6. 发明申请

WO2008058867A3 SUBSTITUTED 4-IMIDAZOLES 审中-公开
标题翻译：取代的4-IMIDAZOLES
公开(公告)号：WO2008058867A3
公开(公告)日：2008-07-10
申请号：PCT/EP2007061921
申请日：2007-11-06
申请人： HOFFMANN LA ROCHE , GALLEY GUIDO , GROEBKE ZBINDEN KATRIN , NORCROSS ROGER , STALDER HENRI
发明人： GALLEY GUIDO , GROEBKE ZBINDEN KATRIN , NORCROSS ROGER , STALDER HENRI
IPC分类号： C07D403/06 , A61K31/4178 , C07D401/06 , C07D413/06
CPC分类号： C07D401/06 , C07D403/06 , C07D413/06
摘要： The present invention relates to compounds of formula (I) wherein R 1 is hydrogen or lower alkyl; R 2 is hydrogen or lower alkyl; R 3 is hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen or lower alkyl substituted by halogen; R 4 is hydrogen or lower alkyl; X is -CH 2 -, -CH- or -O-; Y is -CH 2 -, -CH 2 CH 2 -, -CH- or a bond; when X is -O-, then Y is -CH 2 -; Z is -CH 2 - or -CH-; m is 1 or 2; when m is 2, R 2 may be the same or not; n is 1 or 2; when n is 2, R 3 may be the same or not; and to pharmaceutically acceptable acid addition salts. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及其中R 1为氢或低级烷基的式（I）化合物; R 2是氢或低级烷基; R 3是氢，低级烷基，低级烷氧基，苯氧基，苄氧基，卤素或被卤素取代的低级烷基; R 4是氢或低级烷基; X是-CH 2 - ， - CH-或-O-; Y是-CH 2 - ， - CH 2 CH 2 - ， - CH-或键; 当X是-O-时，则Y是-CH 2 - 。 Z是-CH 2 - 或-CH-; m为1或2; 当m为2时，R 2可以相同或不相同; n为1或2; 当n为2时，R 3可以相同或不相同; 和药学上可接受的酸加成盐。已经发现，式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，特别是对于TAAR1。该化合物可用于治疗抑郁症，焦虑障碍，双相情感障碍，注意力缺陷多动障碍（ADHD），应激相关疾病，精神病性精神障碍如精神分裂症，神经系统疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，物质滥用和代谢紊乱，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病。

7. 发明申请

WO2006114401A3 NOVEL CYCLIC AMINES 审中-公开
公开(公告)号：WO2006114401A3
公开(公告)日：2006-11-02
申请号：PCT/EP2006/061776
申请日：2006-04-24
申请人： F. HOFFMANN-LA ROCHE AG , GROEBKE-ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , PANDAY, Narendra , RICKLIN, Fabienne , WIRZ, Beat
发明人： GROEBKE-ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , PANDAY, Narendra , RICKLIN, Fabienne , WIRZ, Beat
IPC分类号： C07D409/14 , C07D413/14 , C07D401/14 , C07D513/04 , C07D207/16 , C07D207/14 , C07D207/12 , A61K31/4025 , A61P7/02
摘要： The invention is concerned with novel cyclic amines of formula (I) wherein X 1 to X 3 , Y 1 to Y 3 , R 1’ , R 1’’ and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

8. 发明申请

WO2006066778A2 NOVEL HETEROARYLACETAMIDES 审中-公开
标题翻译：新的杂芳基乙酰胺
公开(公告)号：WO2006066778A2
公开(公告)日：2006-06-29
申请号：PCT/EP2005/013460
申请日：2005-12-14
申请人： F. HOFFMANN-LA ROCHE AG , BOEHRINGER, Markus , GROEBKE ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , PANDAY, Narendra , RICKLIN, Fabienne
发明人： BOEHRINGER, Markus , GROEBKE ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , PANDAY, Narendra , RICKLIN, Fabienne
CPC分类号： C07D401/10 , C07D277/46 , C07D409/06 , C07D409/14 , C07D417/06 , C07D417/10 , C07D417/14
摘要： The invention is concerned with novel heteroarylacetamides of formula (I) R d -C(O)-N(R e )-R c -CH 2 -C(O)-N(R a )(R b ), wherein R a to R e are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
摘要翻译：本发明涉及式（I）的新型杂芳基乙酰胺R d -C（O）-N（R e）（O）-N（R a）（R b），其中R 1，R 2，其中R 1至R e如说明书和权利要求中所定义，以及其生理上可接受的盐。这些化合物抑制凝血因子Xa并可以用作药物。

9. 发明申请

WO2006048152A3 DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS 审中-公开
公开(公告)号：WO2006048152A3
公开(公告)日：2006-05-11
申请号：PCT/EP2005/011430
申请日：2005-10-25
申请人： F. HOFFMANN-LA ROCHE AG , BOEHRINGER, Markus , GROEBKE ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , HIMBER, Jacques , HUMM, Roland , IDING, Hans , KNOPP, Dietmar , PANDAY, Narendra , RICKLIN, Fabienne , STAHL, Christoph, Martin
发明人： BOEHRINGER, Markus , GROEBKE ZBINDEN, Katrin , HAAP, Wolfgang , HILPERT, Hans , HIMBER, Jacques , HUMM, Roland , IDING, Hans , KNOPP, Dietmar , PANDAY, Narendra , RICKLIN, Fabienne , STAHL, Christoph, Martin
IPC分类号： C07D213/64 , C07D401/12 , C07D233/54 , C07D213/75 , C07D295/12 , C07D279/02 , C07D295/18 , A61K31/4412 , A61P7/02
摘要： The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, R C , D and E are as defined in the description and in the claims, as well 5as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.

10. 发明申请

WO2011076678A1 SUBSTITUTED BENZAMIDE DERIVATIVES 审中-公开
标题翻译：取代的苯甲酸衍生物
公开(公告)号：WO2011076678A1
公开(公告)日：2011-06-30
申请号：PCT/EP2010/070045
申请日：2010-12-17
申请人： F. HOFFMANN-LA ROCHE AG , GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , PFLIEGER, Philippe
发明人： GROEBKE ZBINDEN, Katrin , NORCROSS, Roger , PFLIEGER, Philippe
IPC分类号： C07D207/09 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D265/30 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , A61K31/4025 , A61K31/4523 , A61K31/5355
CPC分类号： C07D207/09 , A61K9/2018 , C07D207/10 , C07D207/12 , C07D211/26 , C07D241/04 , C07D263/32 , C07D265/30 , C07D267/08 , C07D267/10 , C07D295/135 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D495/04
摘要： The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R 1 is -(CH 2 ) n -(O) o -heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH 2 ) p -aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R 2 is CF 3 , cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF 3 , OCF 3 , OCH 2 CF 3 , OCH 2 -cycloalkyl, OCH 2 C(CH 2 OH)(CH 2 C1)(CH 3 ), S-lower alkyl, lower alkoxy, CH 2 -lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH 2 -phenyl, phenyl or -CH 2 -phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH 2 -oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH 2 NH-, -CHR''-, -(CHR'') q -O-, -O-(CHR'') q - or -(CH 2 ) 2 -; Y is a bond or -CH 2 - R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF 3 , lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
摘要翻译：本发明涉及式I化合物，其中R是氢或低级烷基; R 1是 - （CH 2）n - （O）O-杂环烷基或-C（O） - 杂环烷基，其中杂环烷基任选被低级烷基，羟基，卤素或 - （CH 2） n为0,1或2; o为0或1; p为0,1或2; R2是任选被低级烷氧基或卤素取代的CF 3，环烷基，或者是茚满-2-基，或是任选被杂芳基取代的杂环烷基，或是芳基或杂芳基，其中芳环任选地被一个或两个取代基取代，选自低级烷基，卤素，杂芳基，羟基，CF 3，OCF 3，OCH 2 CF 3，OCH 2 - 环烷基，OCH 2 C（CH 2 OH）（CH 2 Cl）（CH 3），S-低级烷基，低级烷氧基，CH 2 - 低级烷氧基，低级炔基或氰基，或C（O） - 苯基，-O-苯基，-O-CH 2 - 苯基，苯基或-CH 2 - 苯基，并且其中苯环可以任选地被卤素，-C（O） - 低级烷基， -C（O）OH或-C（O）O-低级烷基，或芳环任选被杂环烷基，OCH 2 - 氧杂环丁烷-3-基或O-四氢吡喃-4-基取代，任选被低级烷基取代; X是键，-NR' - ， - CH 2 NH - ， - CHR“ - ， - （CHR”）q-O-，-O-（CHR“）q-或 - （CH 2） Y是一个键或-CH 2 - R'是氢或低级烷基，R“是氢，低级烷基，CF 3，低级烷氧基，q是0,1,2或3; 或其药学上合适的酸加成盐。现已发现，式I化合物对微量胺相关受体（TAAR）具有良好的亲和力，尤其对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍（ADHD），应激相关疾病，精神病性精神障碍如精神分裂症，神经性疾病如帕金森病，神经变性疾病如阿尔茨海默病，癫痫，偏头痛，高血压，药物滥用和代谢障碍如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和同化障碍，体温平衡紊乱和失调，睡眠和昼夜节律紊乱以及心血管疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式